RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions

LeukemiaMantle Cell LymphomaMyelofibrosis

Interventions

DRUG

RAD001

"Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I."

Trial Locations (1)

M.D. Anderson Cancer Center, Houston